Disc Medicine presents Phase 2 RALLY-MF data for DISC-0974 in myelofibrosis anemia

• Disc Medicine flagged new Phase 2 results for DISC-0974 in anemia linked to myelofibrosis, with data already published in an EHA abstract and slated for oral presentation at EHA 2026 in Stockholm on June 12.
• Early readout showed patients across transfusion-status subgroups achieved meaningful anemia improvement, with responses broadly consistent across background treatment settings.
• Company also set EHA updates for its erythropoietic protoporphyria program, including additional long-term extension findings for bitopertin, ahead of an expected Phase 3 readout later in 2026.
• Separate poster will outline progress for DISC-3405 in an ongoing Phase 2 study in polycythemia vera, expanding visibility into Disc’s pipeline beyond the myelofibrosis program.
• Management scheduled a corporate update call for June 15 to review EHA highlights and next steps.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Disc Medicine Inc. i published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605120930PRIMZONEFULLFEED9717964) on May 12, 2026, and is solely responsible for the information contained therein.